Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours

Background: AZD5438 is an orally bioavailable inhibitor of cyclin E-cdk2, cyclin A-cdk2 and cyclin B-cdk1 complexes. Three phase I studies assessed the clinical safety, tolerability, pharmacokinetics and pharmacodynamics of AZD5438 when administered in different dosing schedules. Patients and method...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Boss, D. S., Schwartz, G. K., Middleton, M. R., Amakye, D. D., Swaisland, H., Midgley, R. S., Ranson, M., Danson, S., Calvert, H., Plummer, R., Morris, C., Carvajal, R. D., Chirieac, L. R., Schellens, J. H. M., Shapiro, G. I.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2010
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2844945/
https://ncbi.nlm.nih.gov/pubmed/19825886
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdp377
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados